
R. Paredes¹, F. Lopez-Rios², A. Moore³, A.-M. Baird⁴, T. Gashi⁵, S. Shilo⁶, C. Rolfo^{7*}

¹Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States of America. ⁴President of Lung Cancer Europe, Ireland. ⁵COR2ED (Independent Medical Education Company), Switzerland. ⁵Founder & CEO of the Israeli Lung Cancer Foundation (ILCF), Israel, and Chair of the Patient Advocates Committee at International Association for the Study of Lung Cancer (IASLC), Denver, Colorado, United States of America. *Corresponding author

INTRODUCTION



As targeted therapies increasingly become the standard in treating non-small cell lung cancer (NSCLC), understanding the engagement of patients and caregivers is essential to enhance physician-patient interactions.

Variability in the comprehension of biomarker testing among both people with NSCLC and clinicians can impede effective treatment decisions.

This study aimed to assess the awareness of biomarker testing among patients with NSCLC and those in a caregiving capacity, focusing on improving these interactions for better care outcomes.


METHODS



For patients diagnosed with NSCLC in the past five years and caregivers of people with NSCLC.

Survey was available in five languages:


advocacy groups




The data was analysed by participant type to identify knowledge gaps and Chi-square tests were used to assess differences among categorical variables. Between group comparisons (patient vs caregiver) were not performed.

RESULTS


The survey involved 357 respondents from 37 countries




Most respondents were women (patients 76.3%, caregivers 75.6%) and most caregivers were either a spouse/partner or a son/daughter




Most patients were diagnosed within the last 3 years



Most respondents considered it extremely important to know their biomarker results, although few fully grasped their results




Level of understanding of biomarker results




Knowledge of biomarkers in NSCLC improved after tumour testing, with patients' understanding rising from 2.2% to 27.8% (p<0.01), and caregivers from 4.9% to 26.8% (p=0.01)

Initial and current biomarker knowledge



Despite valuing the biomarker tests, patient and caregiver satisfaction with information quality was mixed, indicating a need for better communication

Satisfaction level of information received



Key respondent recommendations for improving communication

Information source	Patient N=316 n (%)	Caregiver N=41 n (%)
Shortening the time to get the biomarker results	174 (55.1)	23 (56.1)
More information provided about biomarker testing	153 (48.4)	15 (36.6)
More information provided on treatment options	121 (38.3)	18 (43.9)
Easier to understand information about biomarker testing	139 (44.0)	10 (24.4)
Easier to understand information on treatment options	75 (23.7)	8 (19.5)
I am not sure	17 (5.4)	6 (14.6)
Allow more time to take in the information	30 (9.5)	2 (4.9)
Other improvements needed	21 (6.7)	1 (2.4)

The percentages shown reflect the proportion of respondents who answered "Yes" to each option. The remaining percentage, not shown, represents those who did not select that option (i.e. because they felt it did not apply).

CONCLUSIONS

- This global survey has identified substantial gaps in the delivery of accurate and clear communication regarding biomarker testing for people with NSCLC and those in a caregiving capacity.
- These findings highlight the need for healthcare teams to provide more effective communication strategies in this setting to improve healthcare access, outcomes, and advocacy for patients and caregivers.